Fullerton, California Clinical Trials

A listing of Fullerton, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (6.4 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

body mass index
tirzepatide
dulaglutide
cardiovascular disease
Diabetes Associates Medical Group
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

testosterone
cancer
measurable disease
prostatic neoplasms, castration-resistant
combined modality therapy
The University of California, Irvine Medical Center
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibrosis
fibroscan
vcte
fatty liver
hepatic fibrosis
Conquest Clinical Research
 (7.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Core Healthcare Group- Site Number : 8400067
 (7.7 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

small cell lung cancer
lymphoma
stage iv non-small cell lung cancer
measurable disease
drug test
Icri /Id# 217071
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Patient-Derived Xenografts to Reduce Cancer Health Disparities

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

cancer
gastric cancer
liver cancer
biospecimen collection
bladder cancer
UC Irvine Health/Chao Family Comprehensive Cancer Center
 (6.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations